Phathom Pharmaceuticals(PHAT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

PHAT Phathom Pharmaceuticals

Market Closed 11-01 16:00:00 EDT

18.27

+1.12

+6.53%

盘后18.27

+0.000.00%

18:53 EDT

High18.62	Low16.87	Vol1.09M
Open17.39	D1 Closing17.15	Amplitude10.20%
Mkt Cap1.25B	Tradable Cap1.02B	Total Shares68.29M
T/O19.85M	T/O Rate1.96%	Tradable Shares55.66M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"PHAT","market":"US","secType":"STK","nameCN":"Phathom Pharmaceuticals","latestPrice":18.27,"timestamp":1730491200000,"preClose":17.15,"halted":0,"volume":1093626,"hourTrading":{"tag":"盘后","latestPrice":18.27,"preClose":18.27,"latestTime":"18:53 EDT","volume":76525,"amount":1398082.63,"timestamp":1730501584004},"delay":0,"floatShares":55662944,"shares":68289604,"eps":-5.140395,"marketStatus":"Market Closed","change":1.12,"latestTime":"11-01 16:00:00 EDT","open":17.39,"high":18.6191,"low":16.87,"amount":19852311.158497,"amplitude":0.101988,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-5.140395,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Market Trading","tradingStatus":1,"beginTime":1730710800000},"marketStatusCode":7,"adr":0,"listingDate":1571976000000,"exchange":"NASDAQ","adjPreClose":17.15,"preHourTrading":{"tag":"盘前","latestPrice":17.32,"preClose":17.15,"latestTime":"09:29 EDT","volume":387,"amount":6654.050136,"timestamp":1730467799999},"postHourTrading":{"tag":"盘后","latestPrice":18.27,"preClose":18.27,"latestTime":"18:53 EDT","volume":76525,"amount":1398082.63,"timestamp":1730501584004},"volumeRatio":1.2362548483194165,"impliedVol":0.5905,"impliedVolPercentile":0.1429},"requestUrl":"/m/hq/s/PHAT/wiki","defaultTab":"wiki","newsList":[{"id":"2480884254","title":"Investors bid Phathom Pharmaceuticals (NASDAQ:PHAT) up US$75m despite increasing losses YoY, taking one-year return to 96%","url":"https://stock-news.laohu8.com/highlight/detail?id=2480884254","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2480884254?lang=en_us&edition=fundamental","pubTime":"2024-11-01 21:36","pubTimestamp":1730468219,"startTime":"0","endTime":"0","summary":"If you want to compound wealth in the stock market, you can do so by buying an index fund. But you can significantly boost your returns by picking above-average stocks. For example, the Phathom Pharmaceuticals, Inc.  share price is up 96% in the last 1 year, clearly besting the market return of around 30% . That's a solid performance by our standards!In contrast, the longer term returns are negative, since the share price is 23% lower than it was three years ago.Since the stock has added US$75m to its market cap in the past week alone, let's see if underlying performance has been driving long-term returns.Given that Phathom Pharmaceuticals didn't make a profit in the last twelve months, we'll focus on revenue growth to form a quick view of its business development. Shareholders of unprofitable companies usually desire strong revenue growth. As you can imagine, fast revenue growth, when maintained, often leads to fast profit growth.The image below shows how earnings and revenue have tra","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/H9sVDVM9mi9ws1HvXhxW7w--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/8b2f1fb8ed1ddbd9c7702732b1ea0316","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/H9sVDVM9mi9ws1HvXhxW7w--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/8b2f1fb8ed1ddbd9c7702732b1ea0316"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/investors-bid-phathom-pharmaceuticals-nasdaq-133659353.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":[".IXIC","IE00BGHQF748.EUR","PSQ","LU2210150020.SGD","PHAT","MNQmain","BK4585","BK4007","BK4112","QID","LU2095319765.USD","IE00B64PRP62.GBP","QLD","BK4588","SQQQ","LU2210149790.SGD","NDAQ","NQmain","IE00B3QW5Z07.USD","ISBC","TQQQ","BK4211","IE00BKPKM429.USD"],"gpt_icon":1},{"id":"2478104803","title":"BRIEF-Phathom Pharmaceuticals To Report Third Quarter 2024 Financial Results And Provide Business Update On Thursday, November 7, 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2478104803","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2478104803?lang=en_us&edition=fundamental","pubTime":"2024-10-28 20:02","pubTimestamp":1730116927,"startTime":"0","endTime":"0","summary":"Oct 28 (Reuters) - Phathom Pharmaceuticals Inc   :   * PHATHOM PHARMACEUTICALS TO REPORT THIRD QUARTER 2024 FINANCIAL RESULTS AND PROVIDE BUSINESS UPDATE ON THURSDAY, NOVEMBER 7, 2024Source text:    Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4512","BK4007","LU1720051108.HKD","LU1978683503.SGD","LU1854104046.USD","BK4585","BK4141","PHAT","LU1861214812.USD","ON","LU0124384867.USD","LU2357305700.SGD","LU1548497426.USD","LU1854103824.USD","LU1861215975.USD","IE00BD6J9T35.USD","LU2298322129.HKD","BK4588","LU1720051017.SGD","LU0348723411.USD","LU2360107325.USD","LU0724618433.USD","LU1861219969.SGD","IE00BZ199S13.USD","LU1861220033.SGD"],"gpt_icon":0},{"id":"2478010091","title":"Phathom Pharmaceuticals to Report Third Quarter 2024 Financial Results and Provide Business Update on Thursday, November 7, 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2478010091","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2478010091?lang=en_us&edition=fundamental","pubTime":"2024-10-28 20:00","pubTimestamp":1730116849,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241028:nTUATJJZJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PHAT","BK4007"],"gpt_icon":0},{"id":"2478049921","title":"Phathom Pharmaceuticals to Report Third Quarter 2024 Financial Results and Provide Business Update on Thursday, November 7, 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2478049921","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2478049921?lang=en_us&edition=fundamental","pubTime":"2024-10-28 20:00","pubTimestamp":1730116800,"startTime":"0","endTime":"0","summary":"Management to host conference call on Thursday, November 7, 2024, at 8:30 am ET FLORHAM PARK, N.J., Oct.  28, 2024  (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutica","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/10/28/2970035/0/en/Phathom-Pharmaceuticals-to-Report-Third-Quarter-2024-Financial-Results-and-Provide-Business-Update-on-Thursday-November-7-2024.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","PHAT"],"gpt_icon":0},{"id":"2478164669","title":"Phathom Pharmaceuticals to Present VOQUEZNA® Data at the American College of Gastroenterology (ACG) 2024 Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2478164669","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2478164669?lang=en_us&edition=fundamental","pubTime":"2024-10-28 00:00","pubTimestamp":1730044800,"startTime":"0","endTime":"0","summary":"FLORHAM PARK, N.J., Oct.  27, 2024  (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastroi","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/10/27/2969733/0/en/Phathom-Pharmaceuticals-to-Present-VOQUEZNA-Data-at-the-American-College-of-Gastroenterology-ACG-2024-Annual-Meeting.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4107","TEN","BK4007","AFG","BK4124","PHAT","BK4144","BK4117"],"gpt_icon":0},{"id":"2467922770","title":"Phathom Pharmaceuticals Price Target Maintained With a $26.00/Share by Needham","url":"https://stock-news.laohu8.com/highlight/detail?id=2467922770","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2467922770?lang=en_us&edition=fundamental","pubTime":"2024-09-13 23:51","pubTimestamp":1726242660,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/PHAT/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  September 13, 2024 11:51 ET (15:51 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PHAT"],"gpt_icon":0},{"id":"2467775523","title":"Buy Rating Affirmed: Phathom Pharmaceuticals’ V oquezna Shows Promising Market Penetration and Growth Potential","url":"https://stock-news.laohu8.com/highlight/detail?id=2467775523","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2467775523?lang=en_us&edition=fundamental","pubTime":"2024-09-13 21:45","pubTimestamp":1726235121,"startTime":"0","endTime":"0","summary":"Needham analyst Joseph Stringer maintained a Buy rating on Phathom Pharmaceuticals (PHAT – Research Report) today and set a price target of $26.00....","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/buy-rating-affirmed-phathom-pharmaceuticals-v-oquezna-shows-promising-market-penetration-and-growth-potential?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/buy-rating-affirmed-phathom-pharmaceuticals-v-oquezna-shows-promising-market-penetration-and-growth-potential?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PHAT"],"gpt_icon":0},{"id":"2465264820","title":"Phathom Pharmaceuticals Price Target Maintained With a $26.00/Share by Needham","url":"https://stock-news.laohu8.com/highlight/detail?id=2465264820","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2465264820?lang=en_us&edition=fundamental","pubTime":"2024-09-07 01:24","pubTimestamp":1725643440,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/PHAT/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  September 06, 2024 13:24 ET (17:24 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PHAT"],"gpt_icon":0},{"id":"2465692731","title":"Buy Rating for Phathom Pharmaceuticals Amid Strong Voquezna Prescription Growth","url":"https://stock-news.laohu8.com/highlight/detail?id=2465692731","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2465692731?lang=en_us&edition=fundamental","pubTime":"2024-09-06 21:25","pubTimestamp":1725629116,"startTime":"0","endTime":"0","summary":"Analyst Joseph Stringer from Needham maintained a Buy rating on Phathom Pharmaceuticals (PHAT – Research Report) and keeping the price target at $2...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/buy-rating-for-phathom-pharmaceuticals-amid-strong-voquezna-prescription-growth?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/buy-rating-for-phathom-pharmaceuticals-amid-strong-voquezna-prescription-growth?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PHAT"],"gpt_icon":0},{"id":"2463765706","title":"Phathom Pharmaceuticals Price Target Maintained With a $26.00/Share by Needham","url":"https://stock-news.laohu8.com/highlight/detail?id=2463765706","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2463765706?lang=en_us&edition=fundamental","pubTime":"2024-08-31 00:17","pubTimestamp":1725034620,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/PHAT/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  August 30, 2024 12:17 ET (16:17 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PHAT"],"gpt_icon":0},{"id":"2463754265","title":"Phathom Pharmaceuticals’ V oquezna Shows Promising Market Penetration and Drives Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2463754265","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2463754265?lang=en_us&edition=fundamental","pubTime":"2024-08-30 22:45","pubTimestamp":1725029113,"startTime":"0","endTime":"0","summary":"Joseph Stringer, an analyst from Needham, maintained the Buy rating on Phathom Pharmaceuticals (PHAT – Research Report). The associated price targe...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/phathom-pharmaceuticals-v-oquezna-shows-promising-market-penetration-and-drives-buy-rating?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/phathom-pharmaceuticals-v-oquezna-shows-promising-market-penetration-and-drives-buy-rating?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PHAT"],"gpt_icon":0},{"id":"2461543659","title":"Phathom Pharmaceuticals Price Target Maintained With a $26.00/Share by Needham","url":"https://stock-news.laohu8.com/highlight/detail?id=2461543659","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2461543659?lang=en_us&edition=fundamental","pubTime":"2024-08-24 01:30","pubTimestamp":1724434200,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/PHAT/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  August 23, 2024 13:30 ET (17:30 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PHAT"],"gpt_icon":0},{"id":"2461364517","title":"Phathom Pharmaceuticals’ V oquezna: A Rising Star in GERD Treatment Market","url":"https://stock-news.laohu8.com/highlight/detail?id=2461364517","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2461364517?lang=en_us&edition=fundamental","pubTime":"2024-08-24 00:25","pubTimestamp":1724430320,"startTime":"0","endTime":"0","summary":"Analyst Joseph Stringer from Needham maintained a Buy rating on Phathom Pharmaceuticals (PHAT – Research Report) and keeping the price target at $2...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/phathom-pharmaceuticals-v-oquezna-a-rising-star-in-gerd-treatment-market?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/phathom-pharmaceuticals-v-oquezna-a-rising-star-in-gerd-treatment-market?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PHAT","BK4007"],"gpt_icon":0},{"id":"2461877586","title":"These are the Top 3 Most-Shorted Stocks in August 2024; Here’s Why","url":"https://stock-news.laohu8.com/highlight/detail?id=2461877586","media":"CoinMarketCap","labels":["Business Data"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2461877586?lang=en_us&edition=fundamental","pubTime":"2024-08-22 02:29","pubTimestamp":1724264963,"startTime":"0","endTime":"0","summary":"Neither the author, Tim Fries, nor this website, The Tokenist, provide financial advice. Please consult ourwebsite policyprior to making financial decisions.Outside of reading companies’ fundamentals, investing often comes down to reading current market signals against the stock’s daily price. When investors are more confident that the stock price is lower than it should be, they engage in short-selling.But short sellers have to cover their positions, i.e., buy back the shares they borrowed and sold. This introduces the short squeeze dynamic, as it is more difficult to exit short positions without increasing prices.Most commonly, the short interestratio, as the number of total shorted shares divided by the average daily trading volume , is used as a nifty metric to that effect. Specifically, the days-to-cover ratio represents the total number of days for short sellers to repurchase their borrowed shares.Investors should note that short interest data is typically reported with a hefty d","market":"us","thumbnail":"https://academy-public.coinmarketcap.com/srd-optimized-uploads/8d2c2883913c4bb783762f05a1054621.jpeg","type":0,"news_type":0,"thumbnails":["https://academy-public.coinmarketcap.com/srd-optimized-uploads/8d2c2883913c4bb783762f05a1054621.jpeg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://coinmarketcap.com/community/articles/66c632073e55b3333b5c5ada/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"Business Data","news_rank":0,"length":0,"strategy_id":0,"source":"coinmarketcap_highlight","symbols":["BK4122","BK4220","BK4548","GOOG","BK4212","AMZN","QID","BYND","SQQQ","PSQ","PHAT","MNQmain","TQQQ","QLD","BK4007",".IXIC","GRPN","NQmain"],"gpt_icon":1},{"id":"2460039457","title":"Phathom Pharmaceuticals Prices Underwritten Offering of Shares and Warrants","url":"https://stock-news.laohu8.com/highlight/detail?id=2460039457","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2460039457?lang=en_us&edition=fundamental","pubTime":"2024-08-19 21:14","pubTimestamp":1724073275,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_live","symbols":["PHAT","BK4007"],"gpt_icon":0},{"id":"2460595033","title":"Phathom Pharmaceuticals prices $130M equity offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2460595033","media":"seekingalpha","labels":["Shareholding Changes"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2460595033?lang=en_us&edition=fundamental","pubTime":"2024-08-19 20:19","pubTimestamp":1724069968,"startTime":"0","endTime":"0","summary":"Phathom Pharmaceuticals  said it has priced its offering of 8.7Mshares and pre-funded warrants to purchase 2.61Mshares.The shares will be sold at $11.5 apiece, and the pre-funded warrants at $11.499.The gross proceeds are expected to be ~$130 million.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4141400-phathom-pharmaceuticals-prices-130m-equity-offering","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"Shareholding Changes","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha","symbols":["NQmain","SQQQ","MNQmain","QID","QLD",".IXIC","PSQ","PHAT","TQQQ","BK4007"],"gpt_icon":1},{"id":"2460608007","title":"Phathom Pharmaceuticals Announces Pricing of $130 Million Offering of Common Stock and Pre-Funded Warrants","url":"https://stock-news.laohu8.com/highlight/detail?id=2460608007","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2460608007?lang=en_us&edition=fundamental","pubTime":"2024-08-19 20:00","pubTimestamp":1724068819,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20240819:nTUA6LZGLR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","PHAT"],"gpt_icon":0},{"id":"2460080071","title":"Phathom Pharmaceuticals Inc - Prices Underwritten Offering at $11.50 per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2460080071","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2460080071?lang=en_us&edition=fundamental","pubTime":"2024-08-19 20:00","pubTimestamp":1724068819,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20240819:nTUA6LZGLR:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PHAT","BK4007"],"gpt_icon":0},{"id":"2460038540","title":"Phathom Pharmaceuticals Announces Pricing of $130 Million Offering of Common Stock and Pre-Funded Warrants","url":"https://stock-news.laohu8.com/highlight/detail?id=2460038540","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2460038540?lang=en_us&edition=fundamental","pubTime":"2024-08-19 20:00","pubTimestamp":1724068800,"startTime":"0","endTime":"0","summary":"FLORHAM PARK, N.J., Aug.  19, 2024  (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastroi","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/08/19/2932059/0/en/Phathom-Pharmaceuticals-Announces-Pricing-of-130-Million-Offering-of-Common-Stock-and-Pre-Funded-Warrants.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","PHAT"],"gpt_icon":0},{"id":"2460853920","title":"Phathom Pharmaceuticals Price Target Maintained With a $26.00/Share by Needham","url":"https://stock-news.laohu8.com/highlight/detail?id=2460853920","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2460853920?lang=en_us&edition=fundamental","pubTime":"2024-08-19 17:47","pubTimestamp":1724060820,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/PHAT/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  August 19, 2024 05:47 ET (09:47 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PHAT"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.phathompharma.com","stockEarnings":[{"period":"1week","weight":0.1383},{"period":"1month","weight":0.0901},{"period":"3month","weight":0.5873},{"period":"6month","weight":0.8197},{"period":"1year","weight":1.2895},{"period":"ytd","weight":1.0011}],"compareEarnings":[{"period":"1week","weight":-0.0138},{"period":"1month","weight":0.0038},{"period":"3month","weight":0.0716},{"period":"6month","weight":0.1169},{"period":"1year","weight":0.3257},{"period":"ytd","weight":0.2014}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Phathom Pharmaceuticals, Inc., biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. Phathom Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Florham Park, New Jersey.","yearOnYearQuotes":[{"month":1,"riseRate":0.6,"avgChangeRate":-0.023646},{"month":2,"riseRate":0.8,"avgChangeRate":0.124053},{"month":3,"riseRate":0,"avgChangeRate":-0.171034},{"month":4,"riseRate":0.6,"avgChangeRate":0.127165},{"month":5,"riseRate":0.6,"avgChangeRate":-0.027307},{"month":6,"riseRate":0.6,"avgChangeRate":0.044836},{"month":7,"riseRate":0.8,"avgChangeRate":0.051978},{"month":8,"riseRate":0.6,"avgChangeRate":0.096985},{"month":9,"riseRate":0.4,"avgChangeRate":0.002397},{"month":10,"riseRate":0.2,"avgChangeRate":-0.078312},{"month":11,"riseRate":0.5,"avgChangeRate":-0.051235},{"month":12,"riseRate":0.8,"avgChangeRate":0.103809}],"exchange":"NASDAQ","name":"Phathom Pharmaceuticals","nameEN":"Phathom Pharmaceuticals"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Phathom Pharmaceuticals(PHAT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Phathom Pharmaceuticals(PHAT) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Phathom Pharmaceuticals,PHAT,Phathom Pharmaceuticals股票,Phathom Pharmaceuticals股票老虎,Phathom Pharmaceuticals股票老虎国际,Phathom Pharmaceuticals行情,Phathom Pharmaceuticals股票行情,Phathom Pharmaceuticals股价,Phathom Pharmaceuticals股市,Phathom Pharmaceuticals股票价格,Phathom Pharmaceuticals股票交易,Phathom Pharmaceuticals股票购买,Phathom Pharmaceuticals股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Phathom Pharmaceuticals(PHAT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Phathom Pharmaceuticals(PHAT) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction